Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.35 Insider Own12.45% Shs Outstand98.85M Perf Week-3.39%
Market Cap20.55M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float86.55M Perf Month-17.66%
Income-28.06M PEG- EPS next Q- Inst Own41.24% Short Float / Ratio0.08% / 0.12 Perf Quarter-39.95%
Sales47.36M P/S0.43 EPS this Y- Inst Trans-4.31% Short Interest0.07M Perf Half Y-76.78%
Book/sh0.31 P/B0.67 EPS next Y- ROA-35.40% Target Price7.00 Perf Year-78.69%
Cash/sh0.45 P/C0.46 EPS next 5Y- ROE-84.68% 52W Range0.16 - 1.97 Perf YTD-80.01%
Dividend- P/FCF- EPS past 5Y-2.23% ROI-91.97% 52W High-89.45% Beta0.64
Dividend %- Quick Ratio2.05 Sales past 5Y5.42% Gross Margin94.47% 52W Low28.65% ATR0.02
Employees144 Current Ratio2.05 Sales Q/Q263.50% Oper. Margin-46.20% RSI (14)36.41 Volatility7.51% 8.40%
OptionableYes Debt/Eq0.40 EPS Q/Q16.88% Profit Margin-59.25% Rel Volume0.90 Prev Close0.20
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume582.10K Price0.21
Recom1.67 SMA20-11.19% SMA50-20.69% SMA200-65.03% Volume524,279 Change1.76%
Date Action Analyst Rating Change Price Target Change
Mar-13-20Upgrade Robert W. Baird Neutral → Outperform $5
Jul-30-19Downgrade Robert W. Baird Outperform → Neutral
May-14-19Initiated Robert W. Baird Outperform $5
Mar-19-18Initiated Jefferies Buy $12
Mar-19-18Initiated Evercore ISI Outperform $13
Jan-16-18Reiterated H.C. Wainwright Buy $9 → $12
May-30-17Initiated Rodman & Renshaw Buy $9
Aug-05-16Resumed ROTH Capital Buy
Aug-12-15Initiated JMP Securities Mkt Outperform
Jul-27-15Initiated Oppenheimer Outperform $8
Nov-14-23 05:36PM
Sep-25-23 12:00PM
Aug-24-23 12:32PM
Aug-23-23 12:00PM
Aug-17-23 08:00AM
02:02PM Loading…
Jul-19-23 02:02PM
Jul-18-23 01:59PM
Jul-17-23 07:29AM
Jun-23-23 10:50AM
Jun-21-23 07:00AM
Jun-11-23 10:28AM
Jun-02-23 04:30PM
May-22-23 08:00AM
08:00AM Loading…
May-21-23 08:00AM
May-15-23 06:07AM
May-11-23 01:41PM
May-10-23 08:15AM
May-05-23 06:41AM
May-04-23 08:00AM
May-02-23 04:30PM
Apr-17-23 08:00AM
Apr-01-23 12:47PM
Mar-31-23 06:10AM
Mar-29-23 05:00PM
Mar-24-23 05:00PM
07:39AM Loading…
Feb-19-23 07:39AM
Feb-14-23 05:40AM
Jan-17-23 07:10AM
Jan-10-23 08:00AM
Dec-21-22 06:01AM
Nov-23-22 08:00AM
Nov-09-22 08:00AM
Nov-02-22 08:35AM
Nov-01-22 09:15AM
Oct-26-22 08:00AM
Sep-12-22 08:03AM
Sep-08-22 04:01PM
Aug-24-22 10:34AM
Aug-10-22 06:20AM
Aug-04-22 02:03PM
Jul-28-22 07:20AM
Jul-14-22 06:29AM
Jun-02-22 08:00AM
May-18-22 09:35AM
May-16-22 09:35AM
May-11-22 08:45AM
May-04-22 08:00AM
Apr-15-22 11:00AM
Apr-09-22 06:00AM
Apr-08-22 06:15AM
Apr-05-22 12:00PM
Mar-04-22 04:00PM
Mar-01-22 11:05AM
Feb-28-22 09:25AM
Feb-23-22 08:00AM
Feb-04-22 08:58AM
Jan-28-22 08:00AM
Jan-27-22 06:23PM
Jan-16-22 10:30AM
Jan-14-22 08:00AM
Jan-03-22 07:00AM
Dec-15-21 12:53PM
Dec-06-21 09:33AM
Nov-11-21 08:05AM
Nov-08-21 08:00AM
Nov-02-21 09:05AM
Oct-26-21 08:00AM
Oct-14-21 10:00AM
Oct-06-21 08:00AM
Sep-09-21 08:00AM
Sep-08-21 10:31AM
Aug-27-21 10:40AM
Aug-24-21 09:00AM
Aug-06-21 09:42AM
Aug-04-21 09:25AM
Aug-03-21 08:00AM
Jul-28-21 08:00AM
Jun-30-21 08:31AM
Jun-25-21 09:24AM
Jun-24-21 10:03AM
Jun-19-21 05:34AM
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIRITSY CHRISTOPHER PDirectorMay 25Buy0.8510,0008,50020,000May 30 04:21 PM